Posted by Michael Wonder on 17 Dec 2019
Spinraza funding application reviewed by the Rare Disorders Subcommittee
17 December 2019 - PHARMAC has published the Rare Disorders Subcommittee meeting records which recommends Spinraza (nusinersen), a medication for spinal muscular atrophy, is funded in New Zealand.
“We know that people with spinal muscular atrophy, their families and their wider community are wanting to know what stage this funding application is at”, says PHARMAC’s chief executive Sarah Fitt.
The Rare Disorders Subcommittee have recommended that nusinersen be funded with a high priority, for the treatment of children with spinal muscular atrophy, who are not yet showing symptoms. They also recommended nusinersen be funded with a medium priority for the treatment of symptomatic patients with type I, II, and IIIa spinal muscular atrophy.
